Skip to content
HowShorted

CORCEPT THERAPEUTICS INC short interest in 2023

In 2023, CORCEPT THERAPEUTICS INC's disclosed short interest ran from 12.78% of shares outstanding on 13 Jan 2023 to 14.93% on 29 Dec 2023, a change of +2.15 percentage points. The year's high was 17.16% on 28 Apr 2023 and its low 12.78% on 13 Jan 2023, averaging 14.98% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 49.90 days on 14 Jul 2023. Full history: CORCEPT THERAPEUTICS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for CORCEPT THERAPEUTICS INC in 2023

2023 in figures

Start of year
12.78% (13 Jan 2023)
End of year
14.93% (29 Dec 2023)
Change
+2.15 pp
High
17.16% (28 Apr 2023)
Low
12.78% (13 Jan 2023)
Average
14.98%
Highest days to cover
49.90 (14 Jul 2023)
SEC filings marked
8

Every report in 2023

CORCEPT THERAPEUTICS INC short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 202312.78%24.07
31 Jan 202313.45%24.91
15 Feb 202313.53%23.64
28 Feb 202313.80%21.9510-K filed, results (8-K)
15 Mar 202314.42%14.98
31 Mar 202316.68%16.22
14 Apr 202316.65%15.18
28 Apr 202317.16%29.63
15 May 202316.86%21.5110-Q filed, results (8-K)
31 May 202316.47%29.13
15 Jun 202316.51%34.92
30 Jun 202315.66%21.55
14 Jul 202315.49%49.90
31 Jul 202314.70%31.91
15 Aug 202314.50%13.0310-Q filed, results (8-K)
31 Aug 202314.43%32.36
15 Sep 202314.12%19.92
29 Sep 202314.60%15.43
13 Oct 202314.59%21.50
31 Oct 202313.70%25.81
15 Nov 202314.81%14.5610-Q filed, results (8-K)
30 Nov 202314.92%30.10
15 Dec 202314.80%20.84
29 Dec 202314.93%21.55

See also: CORCEPT THERAPEUTICS INC's full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.